证券代码：300272 证券简称：开能健康 公告编号：2023-068 债券代码：123206 债券简称：开能转债 本次公司注册资本及经营范围变更事项的工商变更登记手续已经办理完毕。 近日，公司领取了上海市市场监督管理局换发的《营业执照》。《营业执照》登 记的相关信息如下： ① 具体以本次经上海市市场监督管理局换发的《营业执照》相关内容为准。 开能健康科技集团股份有限公司 关于完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、概况 1、2018年9月3日，开能健康科技集团股份有限公司（以下简称"公司"） 召开2018年第三次临时股东大会，审议通过了《关于提请股东大会授权董事会办 理公司股权激励具体事项的议案》，根据该次股东大会授权，公司董事会已办理 完成了2018年股权激励计划相关的30.048万份股票期权行权事宜，并经中国证券 登记结算有限责任公司深圳分公司审核确认，完成了股份登记手续，因此，公司 总股本由57,687.1469万股增至57,717.1949万股，公司注册资本也随之变动。具体 内容请见公司于2021年10月30日在符 ...

Group 1: Company Overview - Kaineng Health was established in 2001, focusing on whole-house water purification and softening systems for residential, educational, and commercial applications [1] - In the first nine months of 2023, the company achieved a total revenue of CNY 1.24156 billion, maintaining a year-on-year growth of 44.30% [1] Group 2: Sales and Distribution Model - The company employs a direct sales model (DSR) and a distribution model, with direct sales accounting for CNY 0.07 billion, representing 4% of total revenue in 2022 [2] - The distribution model targets mid-range consumers in over 500 cities, with plans to increase the number of distributors to over 600 by the end of 2023 [4] Group 3: International Market Performance - Kaineng's products are sold in over 100 countries, with overseas sales revenue reaching CNY 1.072 billion in 2022, a year-on-year increase of 14.23%, accounting for 65% of total revenue [3] - The average gross margin for the North American subsidiary over the past three years was 42.39%, higher than the overall group gross margin [3] Group 4: Competitive Advantages - The company has a strong competitive edge due to its early entry into the whole-house water purification market and its high localization rate of over 95% for key components [4] - Kaineng's products have received multiple international certifications, enhancing their credibility in global markets [3] Group 5: Future Outlook and Strategic Plans - The company aims to double its sales in three years, focusing on the small water market and increasing brand awareness through offline investments [3] - Kaineng plans to enhance channel development and distributor store expansion to improve market share, with current domestic penetration rates around 20% [4] Group 6: Acquisition Impact - The acquisition of Yuaneng Group shares will enhance Kaineng's decision-making influence and strengthen its strategic layout in the health sector, positively impacting future development [5]

开能健康科技集团股份有限公司投资者关系活动记录表 | 投资者关系活动 | □ 特定对象调研 ； □ 分析师会议 | | --- | --- | | 类别 | □ 媒体采访 □ 业绩说明会 | | | 路演活动 □ 新闻发布会 □ | | | □ 现场交流 | | | √ 其他 （电话交流） | | 参与单位名称及 | 安信证券、光大保德信、开源家电、华西证券 | | 人员姓名 | | | 时间、地点 | 年 月 日 （周二）上午 2023 10 31 10:00-11:00 | | 上市公司 接 | 董事会秘书徐延茂 | | | 一、公司介绍及交流 | | | RO 机等产品，面对人居健康用水群体，包括住宅、学校、医 | | | 院、商业等场景。 | | | 1-9 月公司实现营业总收入 12.4156 亿元，与上年基本持 | | | 平，归属于上市公司股东的净利润为 亿元，较上年同期增 1.29 | | | 长 | | | 2、目前原能集团发展情况如何？ | | | 原能集团是由公司在 年全资设立，核心业务是细胞 2014 | | | 存储，随着业务的不断发展，所需的资金也不断增加，早期也 | | | 域也 ...

证券代码： 300272 证券简称：开能健康 开能健康科技集团股份有限公司投资者关系活动记录表 | 投资者关系活动 □ | 特定对象调研 ； □ 分析师会议 | | --- | --- | | 类别 □ | 媒体采访 □ 业绩说明会 | | □ | 新闻发布会 □路演活动 | | | √现场交流 | | | □其他 （电话交流） | | 参与单位名称及 | 国金证券、汐泰资产、泉汐资产、国君证券、国泰基金、中大君 | | 人员姓名 | 悦、中信证券 | | 时间、地点 | 年 月 日 （周三）上午 2023 10 25 10:00-12:00 | | 上市公司 接 | 董事会秘书徐延茂 | | 待人员姓名 | 证券事务代表陆董英 | | | 一、公司介绍及交流 | | | 1、公司基本情况介绍 | | | 公司成立 年，主要产品为全屋净水机、全屋软水机、 2001 | | | RO 机等产品，面对人居健康用水群体，包括住宅、学校、医 | | | 院、商业等场景。 | | | 1-9 月公司实现营业总收入 12.4156 亿元，与上年基本持 | | 投资者关系活动 | 平，归属于上市公司股东的净利润为 亿元，较 ...

| 证券代码：300272 | 证券简称：开能健康 | 公告编号：2023-067 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 开能健康科技集团股份有限公司 2023年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示 1、本次股东大会召开期间没有增加、否决或者变更议案的情况发生； 2、会议召开的地点：上海浦东新区川大路518号公司会议室。 3、会议召开的方式：本次股东大会采取现场投票和网络投票相结合的方式召开 4、会议召集人：公司董事会 2、本次股东大会不存在变更前次股东大会决议的情形。 一、会议的召开和出席情况 （一）会议召开情况 通过深交所交易系统进行网络投票的时间为：2023年10月26日9:15—9：25，9：30— 11:30 和13:00—15:00； 通过互联网投票系统投票的时间为2023年10月26日上午9:15—下午15:00期间任意时 间。 1、会议召开的时间 （1）现场会议时间：2023年10月26日上午10:00 （2）网络投票时间： 5、 ...

风险提示： 1、现阶段原能集团收入以产业园区租赁及运营服务为主，2023年1-6月该项业 务收入为7,606.72万元，占当期营业收入的86.55%，其他收入占比较小。 2、本次收购完成后，公司将对原能集团的投资调整为一项以权益法核算的长期 股权投资，原能集团的盈利状况将对公司当期损益产生的影响具有重大不确定性。 开能健康科技集团股份有限公司（以下简称"上市公司"或"公司"或"开能 健康"或"开能环保"）于近日收到深圳证券交易所创业板公司管理部下发的《关 于对开能健康科技集团股份有限公司的关注函》（创业板关注函【2023】第 298 号）， 公司高度重视来函事项，现将有关情况公告如下： 1.公告显示，原能集团主要从事围绕细胞深低温第三方存储服务、细胞药物 研发生产、细胞制剂研发生产、细胞因子化妆品研发及相关自动化存储设备的研 发、生产、销售，旗下有多家控股及参股公司。2022 年度原能集团亏损主要由于 计提信用减值损失 2,181.13 万元和资产减值损失 3,378.43 万元，2023 年 1-4 月， 原能集团进一步单项计提其他应收款坏账准备 4,000 万元。请说明： | 证券代码：300272 | ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 | 证券代码：300272 | 证券简称：开能健康 | 公告编号：2023-065 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 开能健康科技集团股份有限公司 关于控股股东、实际控制人部分股份质押的更正公告 开能健康科技集团股份有限公司（以下简称"公司"）于 2023 年 10 月 23 日 披露了《关于控股股东、实际控制人部分股份质押的公告》（公告编号：2023- 064）。 经事后核查发现，因工作人员疏忽，导致部分公告披露内容有误，现将相关 内容更正如下： 更正前： 2、股东股份累计质押的情况 | | | | | | | | | 已质押股份情况 | | 未质押 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | | | | 股份情 | | | | | | | | | | | | 况 | | 股 | | | 本次质 | | | 占公 | ...

| 证券代码：300272 | 证券简称：开能健康 | 公告编号：2023-064 | | --- | --- | --- | | 债券代码：123206 | 债券简称：开能转债 | | 开能健康科技集团股份有限公司 关于控股股东、实际控制人部份股份质押的公告 2、股东股份累计质押的情况 截至本公告披露日，上述股东及其一致行动人所持质押股份情况如下： 第 1 页 共 2 页 | | | | | | | 占公 | 已质押股份情 | | 未质押股份情 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 司 | 况 | | 况 | | | | | | | | | 总股 | | | | | | | | | 本次 | | | 本比 | 已质 | | | | | 股 | | | 质押 | 本次质 | 占其 | 例 | 押股 | | 未质 | | | 东 | 持股 | 持股 | 前质 | 押后质 | 所持 | | 份限 | 占已 | 押股 | 占未 | | 名 | 数量 | 比例 | 押股 | 押股份 | ...

Financial Performance - The company's revenue for Q3 2023 was ¥445,856,818.05, a decrease of 10.21% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2023 was ¥75,536,379.78, an increase of 29.27% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥48,151,031.61, down 10.09% from the previous year[5] - Basic earnings per share for Q3 2023 were ¥0.13, an increase of 18.18% compared to the same period last year[5] - Net profit for Q3 2023 was CNY 147,975,036.86, an increase of 45.2% compared to CNY 101,936,358.39 in the same period last year[24] - The total comprehensive income for the third quarter was CNY 156,594,928.39, an increase from CNY 115,295,150.80 in the previous year, representing a growth of approximately 35.9%[25] - Basic and diluted earnings per share increased to CNY 0.23 from CNY 0.16, reflecting a growth of 43.75% year-over-year[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,815,523,631.16, representing a 21.67% increase from the end of the previous year[5] - The company's total assets increased to CNY 2,815,523,631.16 from CNY 2,314,014,391.36, reflecting a growth of approximately 21.7%[22] - Total liabilities rose to CNY 1,553,443,450.72, up from CNY 1,196,530,910.78, indicating an increase of about 29.9%[22] - The equity attributable to shareholders of the parent company increased to CNY 1,205,023,876.79 from CNY 1,090,276,172.70, a growth of approximately 10.5%[22] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥287,487,661.81, a significant increase of 383.47%[5] - The net cash flow from operating activities reached 287.49 million, representing a significant increase of 383.47% year-on-year[11] - Cash and cash equivalents at the end of the period reached CNY 963,571,041.02, compared to CNY 299,528,280.69 at the end of the previous year, marking an increase of 221.5%[28] - The company reported cash inflow from financing activities of CNY 885,776,174.49, up from CNY 357,448,705.85, which is an increase of 147.0% year-over-year[28] - Total cash outflow from operating activities was CNY 1,019,915,474.48, down from CNY 1,253,714,473.84, indicating a decrease of 18.7%[27] Investments and Acquisitions - The company approved the acquisition of a 12.87% stake in Yuaneng Group for CNY 26,710.6345 million, pending shareholder approval[18] - The board meeting approved the acquisition with a unanimous vote of 4 in favor, indicating strong internal support for the transaction[18] - The company recognized a fair value change gain of approximately 27.50 million from its holdings in Yuan Energy Group[10] - The company did not report any cash inflow from investment activities related to the acquisition of subsidiaries during the quarter[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,808[13] - The minority shareholders' profit increased by 51.47% to 18.66 million, driven by profit growth in non-wholly-owned subsidiaries[10] Operational Metrics - Total operating revenue for Q3 2023 was CNY 1,241,561,388.15, slightly down from CNY 1,243,354,932.90 in Q3 2022, representing a decrease of approximately 0.15%[23] - Total operating costs decreased to CNY 1,114,267,143.22 from CNY 1,126,946,208.17, a reduction of about 1.15%[23] - Research and development expenses for Q3 2023 were CNY 46,709,367.04, slightly up from CNY 45,227,843.50, indicating a year-over-year increase of about 3.3%[23] Financial Health and Future Plans - The company plans to continue expanding its market presence and product offerings in the upcoming quarters, focusing on innovation and strategic acquisitions[18] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[22] - The company’s total liabilities and equity figures will be detailed in the upcoming financial statements, reflecting ongoing financial health assessments[19] Other Financial Details - Financial expenses surged to 10.72 million, a dramatic increase of 2014.32% due to increased borrowing costs[10] - Investment losses amounted to -6.55 million, reflecting a 96.96% increase in losses from associated companies[10] - The company reported a significant increase in fair value gains, amounting to CNY 27,504,310.73 compared to a loss of CNY 1,139,609.92 in the previous year[24] - The report was not audited, indicating that the figures presented are subject to further verification[29]